Synaptogenix Inc (NASDAQ:SNPX) — Market Cap & Net Worth
Market Cap & Net Worth: Synaptogenix Inc (SNPX)
Synaptogenix Inc (NASDAQ:SNPX) has a market capitalization of $8.09 Million ($8.09 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27668 globally and #5705 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Synaptogenix Inc's stock price $5.82 by its total outstanding shares 1389820 (1.39 Million). Also see SNPX total asset value for a full breakdown of the balance sheet.
Synaptogenix Inc Market Cap History: 2020 to 2025
Synaptogenix Inc's market capitalization history from 2020 to 2025. Data shows change from $208.47 Million to $8.09 Million (-43.44% CAGR). Also see cash flow conversion of Synaptogenix Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Synaptogenix Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #795 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2553 of 3165 |
Weight: Synaptogenix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Synaptogenix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Synaptogenix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Synaptogenix Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of SNPX by Market Capitalization
Companies near Synaptogenix Inc in the global market cap rankings as of September 18, 2026. Review SNPX tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Synaptogenix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Synaptogenix Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Synaptogenix Inc's market cap moved from $208.47 Million to $ 8.09 Million, with a yearly change of -43.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $8.09 Million | +67.72% |
| 2024 | $4.82 Million | -48.97% |
| 2023 | $9.45 Million | -76.55% |
| 2022 | $40.30 Million | -86.37% |
| 2021 | $295.68 Million | +41.83% |
| 2020 | $208.47 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 28th, 2026 the market cap of Synaptogenix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.09 Million USD |
| MoneyControl | $8.09 Million USD |
| MarketWatch | $8.09 Million USD |
| marketcap.company | $8.09 Million USD |
| Reuters | $8.09 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Synaptogenix Inc
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X synd… Read more